[SEC Concludes Investigation of Sinovac About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccine]
[1 Announcement dated August 17, 2018 in respect of Appointment of Executive Directors. build-out the Companys ability to effectively sustain its growth and to achieve or enhance profitability; changes in the PRC telecommunications industry resulting from the issuance of licenses for telecommu]
[FORM 10−Q (Mark One) [X] For the quarterly period ended: June 30, 2018 [ ] For the transition period from _____________ to _____________ 001-32898 CBAK ENERGY TECHNOLOGY, INC. Nevada 88-0442833 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) BAK In]
[SEC Concludes Investigation of Sinovac About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccine]
[Dunxin Financial Holdings Limited Reports Financial Results for the First Six Months of 2018 WUHAN, HUBEI, China—August 20, 2018—Dunxin Financial Holdings Limited (“Dunxin” or the “Company”) (NYSE American: DXF), a leading licensed microfinance lender serving individuals and small and medium enterpr]
[Major Shareholders of China Automotive Systems Announce Withdrawal WUHAN, China, August 20, 2018 — China Automotive Systems, Inc. (NASDAQ: CAAS) In a letter dated August 30, 2017 from Mr. Hanlin Chen, chairman of the Company, and his affiliates, including Wiselink Holdings Limited, a company control]
[JOINT FILING AGREEMENT [Remainder of Page Intentionally Left Blank] GL Trade Investment Limited Hu Chou Hui Director GL China Opportunities Fund L.P. Zhenfu Li Authorized Signatory GL Capital Management GP L.P. Zhenfu Li Authorized Signatory GL Capital Management GP Limited Zhenfu Li Director GL Par]
[Number Page 1.1 Announcement of interim results for the six months ended 30 June 2018, dated August 20, 2018 A-1 6-K our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans; our operations and business ]
[PROPOSAL LETTER August 17, 2018 The Board of Directors China Biologic Products Holdings, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China Dear Members of the Board of Directors: Mr. Gao GL Capital BOCGI CDH Consortium ]
